NeoGenomics Total Liab vs Other Current Liab Analysis

NEO Stock

USD 14.80 0.19 1.27%

NeoGenomics financial indicator trend analysis is infinitely more than just investigating NeoGenomics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeoGenomics is a good investment. Please check the relationship between NeoGenomics Total Liab and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

Total Liab vs Other Current Liab

Total Liab vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeoGenomics Total Liab account and Other Current Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between NeoGenomics' Total Liab and Other Current Liab is 0.69. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of NeoGenomics, assuming nothing else is changed. The correlation between historical values of NeoGenomics' Total Liab and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of NeoGenomics are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Liab i.e., NeoGenomics' Total Liab and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Other Current Liab

Most indicators from NeoGenomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeoGenomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.At this time, NeoGenomics' Selling General Administrative is very stable compared to the past year. As of the 17th of May 2024, Sales General And Administrative To Revenue is likely to grow to 0.74, while Tax Provision is likely to drop (9.6 M).

	2021	2022	2023	2024 (projected)
Interest Expense	5.1M	1.5M	6.9M	7.3M
Depreciation And Amortization	53.4M	69.2M	72.6M	76.2M

Interest Expense Depreciation And Amortization

NeoGenomics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Property Plant Equipment	Short Long Term Debt Total	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Net Receivables
Total Assets		0.64	0.93	0.99	0.87	-0.69	0.5	0.96	0.98	-0.19	0.89	0.98	0.99	0.99	-0.19	0.99	1.0	0.79	0.96	0.98	0.93	0.98	0.78	-0.07	0.28	0.93
Other Current Liab	0.64		0.61	0.6	0.66	-0.67	-0.26	0.63	0.58	-0.15	0.55	0.69	0.69	0.59	-0.15	0.58	0.67	0.45	0.59	0.68	0.68	0.69	0.32	0.28	-0.12	0.59
Total Current Liabilities	0.93	0.61		0.94	0.78	-0.68	0.59	0.88	0.86	-0.33	0.96	0.89	0.91	0.91	-0.33	0.93	0.94	0.77	0.87	0.89	0.86	0.89	0.72	0.01	0.33	0.98
Total Stockholder Equity	0.99	0.6	0.94		0.82	-0.63	0.55	0.96	0.98	-0.2	0.9	0.96	0.97	0.99	-0.2	1.0	0.99	0.8	0.96	0.96	0.94	0.96	0.81	-0.03	0.35	0.95
Net Debt	0.87	0.66	0.78	0.82		-0.76	0.3	0.74	0.8	-0.15	0.7	0.93	0.92	0.8	-0.15	0.81	0.9	0.59	0.81	0.9	0.78	0.93	0.56	-0.37	-0.08	0.74
Retained Earnings	-0.69	-0.67	-0.68	-0.63	-0.76		-0.18	-0.67	-0.61	0.17	-0.62	-0.75	-0.75	-0.63	0.17	-0.63	-0.71	-0.54	-0.7	-0.77	-0.45	-0.77	-0.39	0.25	0.09	-0.67
Accounts Payable	0.5	-0.26	0.59	0.55	0.3	-0.18		0.45	0.48	-0.22	0.61	0.4	0.42	0.52	-0.22	0.56	0.48	0.52	0.5	0.41	0.36	0.4	0.53	-0.28	0.53	0.61
Cash	0.96	0.63	0.88	0.96	0.74	-0.67	0.45		0.98	-0.16	0.85	0.94	0.94	0.98	-0.16	0.97	0.94	0.82	0.97	0.96	0.88	0.94	0.77	0.07	0.37	0.9
Cash And Short Term Investments	0.98	0.58	0.86	0.98	0.8	-0.61	0.48	0.98		-0.15	0.83	0.96	0.96	0.99	-0.15	0.98	0.96	0.79	0.97	0.97	0.92	0.96	0.79	-0.03	0.35	0.87
Common Stock Total Equity	-0.19	-0.15	-0.33	-0.2	-0.15	0.17	-0.22	-0.16	-0.15		-0.52	-0.16	-0.18	-0.19	1.0	-0.2	-0.19	-0.36	-0.17	-0.16	-0.21	-0.16	0.23	-0.03	-0.08	-0.31
Common Stock Shares Outstanding	0.89	0.55	0.96	0.9	0.7	-0.62	0.61	0.85	0.83	-0.52		0.83	0.86	0.88	-0.52	0.9	0.89	0.8	0.84	0.84	0.83	0.84	0.63	0.03	0.36	0.97
Non Current Liabilities Total	0.98	0.69	0.89	0.96	0.93	-0.75	0.4	0.94	0.96	-0.16	0.83		1.0	0.96	-0.16	0.96	0.99	0.76	0.96	1.0	0.9	1.0	0.73	-0.16	0.16	0.88
Total Liab	0.99	0.69	0.91	0.97	0.92	-0.75	0.42	0.94	0.96	-0.18	0.86	1.0		0.97	-0.18	0.96	0.99	0.77	0.96	1.0	0.91	1.0	0.73	-0.14	0.18	0.9
Total Current Assets	0.99	0.59	0.91	0.99	0.8	-0.63	0.52	0.98	0.99	-0.19	0.88	0.96	0.97		-0.19	0.99	0.97	0.8	0.97	0.97	0.93	0.96	0.79	-0.01	0.37	0.92
Common Stock	-0.19	-0.15	-0.33	-0.2	-0.15	0.17	-0.22	-0.16	-0.15	1.0	-0.52	-0.16	-0.18	-0.19		-0.2	-0.19	-0.36	-0.17	-0.16	-0.21	-0.16	0.23	-0.03	-0.08	-0.31
Property Plant And Equipment Net	0.99	0.58	0.93	1.0	0.81	-0.63	0.56	0.97	0.98	-0.2	0.9	0.96	0.96	0.99	-0.2		0.98	0.78	0.95	0.96	0.93	0.96	0.81	-0.01	0.4	0.94
Non Current Assets Total	1.0	0.67	0.94	0.99	0.9	-0.71	0.48	0.94	0.96	-0.19	0.89	0.99	0.99	0.97	-0.19	0.98		0.78	0.95	0.98	0.93	0.99	0.77	-0.11	0.22	0.93
Other Current Assets	0.79	0.45	0.77	0.8	0.59	-0.54	0.52	0.82	0.79	-0.36	0.8	0.76	0.77	0.8	-0.36	0.78	0.78		0.85	0.77	0.72	0.76	0.48	-0.09	0.11	0.8
Other Stockholder Equity	0.96	0.59	0.87	0.96	0.81	-0.7	0.5	0.97	0.97	-0.17	0.84	0.96	0.96	0.97	-0.17	0.95	0.95	0.85		0.96	0.86	0.96	0.7	-0.07	0.29	0.88
Property Plant And Equipment Gross	0.98	0.68	0.89	0.96	0.9	-0.77	0.41	0.96	0.97	-0.16	0.84	1.0	1.0	0.97	-0.16	0.96	0.98	0.77	0.96		0.89	1.0	0.74	-0.13	0.19	0.89
Property Plant Equipment	0.93	0.68	0.86	0.94	0.78	-0.45	0.36	0.88	0.92	-0.21	0.83	0.9	0.91	0.93	-0.21	0.93	0.93	0.72	0.86	0.89		0.89	0.73	0.11	0.28	0.86
Short Long Term Debt Total	0.98	0.69	0.89	0.96	0.93	-0.77	0.4	0.94	0.96	-0.16	0.84	1.0	1.0	0.96	-0.16	0.96	0.99	0.76	0.96	1.0	0.89		0.72	-0.15	0.16	0.88
Current Deferred Revenue	0.78	0.32	0.72	0.81	0.56	-0.39	0.53	0.77	0.79	0.23	0.63	0.73	0.73	0.79	0.23	0.81	0.77	0.48	0.7	0.74	0.73	0.72		-0.02	0.41	0.75
Non Currrent Assets Other	-0.07	0.28	0.01	-0.03	-0.37	0.25	-0.28	0.07	-0.03	-0.03	0.03	-0.16	-0.14	-0.01	-0.03	-0.01	-0.11	-0.09	-0.07	-0.13	0.11	-0.15	-0.02		0.53	0.05
Other Assets	0.28	-0.12	0.33	0.35	-0.08	0.09	0.53	0.37	0.35	-0.08	0.36	0.16	0.18	0.37	-0.08	0.4	0.22	0.11	0.29	0.19	0.28	0.16	0.41	0.53		0.38
Net Receivables	0.93	0.59	0.98	0.95	0.74	-0.67	0.61	0.9	0.87	-0.31	0.97	0.88	0.9	0.92	-0.31	0.94	0.93	0.8	0.88	0.89	0.86	0.88	0.75	0.05	0.38

Click cells to compare fundamentals

NeoGenomics Account Relationship Matchups

NeoGenomics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	709.5M	988.3M	1.9B	1.7B	1.7B	1.8B
Other Current Liab	(1.6M)	(4.0M)	56.1M	(7.6M)	68.2M	71.6M
Total Current Liabilities	63.9M	73.2M	87.2M	89.9M	96.3M	101.1M
Total Stockholder Equity	507.4M	694.3M	1.1B	998.0M	941.5M	988.6M
Net Debt	(40.1M)	(10.5M)	296.0M	347.7M	269.2M	282.7M
Retained Earnings	(11.4M)	(7.2M)	(14.8M)	(159.1M)	(247.1M)	(234.7M)
Accounts Payable	50.1M	65.4M	17.9M	83.3M	20.3M	16.6M
Cash	173.0M	228.7M	316.8M	263.2M	342.5M	359.6M
Cash And Short Term Investments	173.0M	296.3M	515.4M	438.0M	415.2M	436.0M
Common Stock Total Equity	105K	112K	124K	127K	114.3K	102.7K
Common Stock Shares Outstanding	103.6M	111.8M	120.0M	124.2M	125.5M	131.8M
Liabilities And Stockholders Equity	709.5M	988.3M	1.9B	1.7B	1.7B	1.8B
Non Current Liabilities Total	138.2M	220.9M	674.3M	652.1M	643.4M	675.6M
Total Liab	202.1M	294.0M	761.5M	742.0M	739.7M	776.7M
Total Current Assets	290.7M	448.7M	681.5M	605.3M	596.8M	626.7M
Common Stock	105K	112K	124K	127K	114.3K	102.7K
Property Plant And Equipment Net	90.7M	151.9M	211.7M	198.6M	183.8M	193.0M
Non Current Assets Total	418.8M	539.6M	1.2B	1.1B	1.1B	1.1B
Other Current Assets	9.1M	4.6M	8.2M	8.1M	8.2M	8.7M
Other Stockholder Equity	520.3M	701.4M	1.1B	1.2B	1.2B	1.2B
Property Plant And Equipment Gross	90.7M	131.7M	321.6M	330.5M	342.0M	359.1M
Accumulated Other Comprehensive Income	(1.6M)	10K	(638K)	(3.9M)	(1.7M)	(1.8M)
Property Plant Equipment	64.2M	85.9M	211.7M	102.5M	117.9M	123.8M
Short Long Term Debt Total	132.9M	218.2M	612.8M	610.9M	611.7M	642.3M
Current Deferred Revenue	1.6M	4.0M	5.2M	7.6M	2.1M	2.2M
Non Currrent Assets Other	2.8M	21.0M	7.2M	(29.7M)	4.7M	5.0M
Other Assets	2.8M	54.4M	7.2M	5.1M	5.9M	3.8M
Net Receivables	94.2M	106.8M	112.1M	119.7M	131.2M	137.8M
Inventory	14.4M	29.5M	23.4M	24.3M	24.2M	25.4M
Short Term Debt	13.8M	7.8M	8.0M	6.7M	5.6M	7.7M
Long Term Debt	91.8M	168.1M	532.5M	535.3M	538.2M	565.1M
Other Liab	17.1M	10.4M	69.5M	47.8M	55.0M	57.7M
Net Tangible Assets	182.2M	362.6M	138.8M	67.0M	77.0M	70.4M
Good Will	198.6M	211.1M	527.1M	522.8M	601.2M	631.2M
Retained Earnings Total Equity	(11.4M)	(7.2M)	(14.8M)	(159.1M)	(143.2M)	(136.0M)
Long Term Debt Total	115.9M	168.1M	532.5M	535.3M	615.6M	646.4M
Capital Surpluse	520.3M	701.4M	1.1B	1.2B	1.3B	1.4B
Capital Lease Obligations	24.0M	50.1M	80.3M	75.6M	73.5M	77.2M
Deferred Long Term Liab	15.6M	5.4M	55.5M	34.8M	40.0M	42.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:

How To Invest In NeoGenomics

Details

Is NeoGenomics Stock a good investment?

Details

What is NeoGenomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

Note that the NeoGenomics information on this page should be used as a complementary analysis to other NeoGenomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for NeoGenomics Stock analysis

When running NeoGenomics' price analysis, check to measure NeoGenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoGenomics is operating at the current time. Most of NeoGenomics' value examination focuses on studying past and present price action to predict the probability of NeoGenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoGenomics' price. Additionally, you may evaluate how the addition of NeoGenomics to your portfolios can decrease your overall portfolio volatility.

	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	FinTech Suite Use AI to screen and filter profitable investment opportunities

Is NeoGenomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.306

Earnings Share

(0.66)

Revenue Per Share

4.855

Quarterly Revenue Growth

0.139

Return On Assets

(0.03)

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeoGenomics Total Liab vs Other Current Liab Analysis

Total Liab vs Other Current Liab

Total Liab vs Other Current Liab Correlation Analysis

Correlation Coefficient

Total Liab

Other Current Liab

NeoGenomics fundamental ratios Correlations

NeoGenomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NeoGenomics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for NeoGenomics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total

Short Long Term Debt Total	- 0.77	Retained Earnings
Property Plant And Equipment Gross	- 0.77	Retained Earnings
Retained Earnings	- 0.76	Net Debt
Total Liab	- 0.75	Retained Earnings
Non Current Liabilities Total	- 0.75	Retained Earnings
Non Current Assets Total	- 0.71	Retained Earnings